Comparison of preventive and therapeutic effect on cardio-cerebral ischemic disease between Salvianolic acids and Aspirin

[Speaker] Juntian Zhang:1
[Co-author] Guanhua Du:1, Shifeng Chu:1
1:Institute of Materia Medica, Chinese Academy of Medical Sciences, China

Aspirin (AS) has been widely used globally for preventing incidence of cardio-cerebral ischemic disease, but many persons were died from interned bleeding. We found salvianolic acids (SA) was much better than AS in preventing incidence of cardio cerebral ischemic disease, and may avoid hemorrhage risk in clinical application. The research are summary briefly as follows: 1. both AS and AS have same antiplatelet aggregation effect, but their mechanism is different. AS inhibited both TXA2 and PGI2. ,SA inhibited TXA2 only; 2.For established thrombosis, SA could dissolved it, AS showed no effect. 3. In SHRSP rats, the incidence of stroke and death rate in SA group was distinct less that of AS group; 4. In MCAO rats, SA decreased stroke index and neural impairment. AS showed no such ability; 5. There is microcirculatory disturbance in cardio cerebral ischemic disease. SA could improve circulatory disturbance induced by LPS, adrenaline, ROS and I/R. there is no any paper reported AS could have beneficial effect; 6. SA showed significant hypolipidemic effect which is similar to that of statins (atorvastatin and simvastatin). AS has no inhibitory effect on hyperlipidemia. 7. There is overproduction of ROS induced by ischemic/reperfusion, SA showed more robust, antioxidant capacity than VitC, Vit E, melatonin, edalavone and resveratrol, etc. 8. About1/3 patients who take AS for long time will have hemorrhage, we found in normal rats and mice (coagulating and hemodynamics) SA had no apparent effect on coagulation system and this property of SA was confirmed in clinic trial with hundred thousand cases; 9. We proved that SA could inhibit Abeta aggregation and fiber formation, inhibit tau hyperphosphorylation induced by OA and p25/CDK5, as well as increase neurogenesis and angiogenesis. More importantly, SA showed not only preventive effect on cardio cerebral vascular diseases. The therapeutic effect of SA is characterized by inducing multi-target effect and inhibit pathogenesis of early, middle and late stage of stroke. SA as anti-stroke new drug was approved by the state food and drug administration of China in 2011.

Advanced Search